CD133 or prominin-1 was proposed as a biomarker of tumor progression/initiation cells described in glioblastoma [106], but it appeared later to be insufficient as CD133-negative cells were also able to initiate tumors [107]. The gene discussed is PROM1; the disease is neoplasm.